YAP1 and breast carcinoma: To investigate whether MAP3K3 inhibition suppresses YAP activity in breast cancer cells resistant to the CDK4/6 inhibitor palbociclib, we established palbociclib-resistant MCF7 (MCF7_PalR) and T47D (T47D_PalR) cell lines by chronic drug administration.